View On Demand

Stress Biology is a $60B Whitespace in Healthcare

About the Event

The diagnostic market for stress-related diseases is $60B. Inmedix has developed the first device that precisely measures stress biology based on next-generation heart rate variability (HRV) testing. It’s a proprietary SaaS platform with two recurrent revenue streams and 90% SaaS margins. 

Joint our Fireside Chat to hear more about the science and why Inmedix has the potential to become a multi-unicorn from:

  • Bernie Tobin, General Manager, Natera, an experienced pharma executive with leadership positions at Amgen, Lilly, and most recently Crescendo Bioscience.
  • David Sun, CEO, Coaching International and an active coach. He has founded global tech firms, and served as Chief Strategy Officer or a major Family Office and PE firm.
  • Andrew Holman MD, CEO, Inmedix, Dr. Holman is the Inc PS, Director of Research at Pacific Rheumatology Research Inc., and founder of Inmedix.

View On-Demand


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.